Interestingly, previous studies involving large cohorts of PCNSL patients receiving a uniform chemotherapy regimen of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) indicated that the MYD88 L265P and CD79B Y196 mutations were associated with prognosis (Nakamura et al., 2016; Nayyar et al., 2019). Here, MYD88 is linked to primary central nervous system lymphoma.